The Current Management And Costs Of Irritable Bowel Syndrome With Constipation In Belgium: A 2-Round Expert Survey
VALUE IN HEALTH(2013)
Abstract
Patients suffering from irritable bowel syndrome (IBS) with constipation (IBS-C) receive laxatives as first line therapy. In spite of these laxatives most of them experience failure. We aimed at describing the current management and its costs of Belgian IBS-C patients who failed first line treatment. A 2-round Delphi panel was conducted including general practitioners (GP) and gastroenterologists. The type and frequency of medical resources used per year as second-line IBS-C therapy (consultations, exams/tests, drugs, hospitalizations) were collected, reflecting the expert’s own practice in the first round and finding a Belgian consensus in the second round. Two patients’ profiles were defined: second line current management and third line management in case of second line failure. Unit costs (2012 INAMI/RIZIV tariffs) were assigned to the resources used to calculate a cost per patient-year and a range based on the distribution of experts’ answers. Eleven experts participated (6 GPs/5 gastroenterologists). The drugs prescribed in second line were laxatives (71.4%, mainly osmotics), spasmolytics (72.2%), pain killers (11.5%) and antidepressants (6.0%). There were 7.7 consultations per patient-year on average (GP: 5.3; specialists: 2.4). Emergency room visits occurred in 10.4% and diagnostic tests included thyroid function (79.1%), rectosigmoidoscopy (39.8%) and abdominal echography (36.8%). There were 0.97 IBS-related admissions to hospital per patient-year. After a second line failure, resource use increased with more laxatives (75.5%), antidepressants (24.6%) and pain killers (17.3%), 11.6 consultations (GP: 7.5; specialist: 4.1), 14.5% emergency room visits and 1.25 hospitalizations. Diagnostic tests were also more frequent (rectosigmoidoscopy: 49.3%; abdominal echography: 43.6%) except thyroid function (70.0%). The annual cost of second line was €2,114 [1,509;2,819] versus €2,920 [2,072;3,917] after second line failure. Hospitalizations accounted for about 75% of the costs. IBS with constipation leads to significant resource use and high costs certainly in case of second line treatment failure.
MoreTranslated text
Key words
irritable bowel syndrome,constipation
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined